News

The advancement of the compound into the pre-clinical development triggers an agreed milestone payment to Evotec, under the collaboration signed in March 2008. Evotec chief operating officer Dr

The company anticipates launching both the brands into mass market retailers in the first quarter of 2013. Inergetics CMO Jim Kras said, "The incorporation of our brands allows

The study is designed to assess the safety and immunogenicity of the company’s vaccine in HIV-positive patients who can control infections using oral HIV drug medication. GeoVax president

STI president and chief executive officer Henry Ji said, "With the acquisition of the proprietary rights to the rIVIG technology, we now have access to a multi-billion dollar

Hikma will pay EGP142.4m ($22.2 m) in cash as part of the the acquisition that expects to strengthen the company’s position in the Egyptian market. The transaction will

Supporting blood bank screening, medical diagnostics and drug discovery services, Lab21’s products division manufactures immunodiagnostic kits and reagents for healthcare providers, pharmaceutical and diagnostic companies. Lab21 CFO Susan

Under the purchase, OPKO intends to include Cytochroma’s Replidea and Alpharen, which are in Phase 3 clinical trials with kidney disease patients, into its product portfolio. Vitamin D

Transfer of all assets and liabilities of MorphoSys’ research and diagnostic antibody segment, the AbD Serotec, in addition to all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys

The project that is scheduled for three years and is being funded by IWT, will focus on advancing the development of the company’s candidate drug targeting DNA pol